ZED1227 is a transglutaminase 2 (TG2) inhibitor developed by Zedira GmbH for celiac disease[1][2] and nonalcoholic steatohepatitis.[3]
Legal status | |
---|---|
Legal status |
|
Identifiers | |
| |
PubChem CID | |
Chemical and physical data | |
Formula | C26H36N6O6 |
Molar mass | 528.610 g·mol−1 |
3D model (JSmol) | |
| |
|
References
edit- ^ Schuppan, Detlef; Mäki, Markku; Lundin, Knut E.A.; Isola, Jorma; Friesing-Sosnik, Tina; Taavela, Juha; Popp, Alina; Koskenpato, Jari; Langhorst, Jost; Hovde, Øistein; Lähdeaho, Marja-Leena; Fusco, Stefano; Schumann, Michael; Török, Helga P.; Kupcinskas, Juozas; Zopf, Yurdagül; Lohse, Ansgar W.; Scheinin, Mika; Kull, Karin; Biedermann, Luc; Byrnes, Valerie; Stallmach, Andreas; Jahnsen, Jørgen; Zeitz, Jonas; Mohrbacher, Ralf; Greinwald, Roland (1 July 2021). "A Randomized Trial of a Transglutaminase 2 Inhibitor for Celiac Disease". New England Journal of Medicine. 385 (1): 35–45. doi:10.1056/NEJMoa2032441. hdl:10852/92293. PMID 34192430. S2CID 235697132.
- ^ Büchold, Christian; Hils, Martin; Gerlach, Uwe; Weber, Johannes; Pelzer, Christiane; Heil, Andreas; Aeschlimann, Daniel; Pasternack, Ralf (17 May 2022). "Features of ZED1227: The First-In-Class Tissue Transglutaminase Inhibitor Undergoing Clinical Evaluation for the Treatment of Celiac Disease". Cells. 11 (10): 1667. doi:10.3390/cells11101667. PMC 9139979. PMID 35626704.
- ^ "CTG Labs - NCBI". clinicaltrials.gov. Retrieved 3 December 2023.